142 related articles for article (PubMed ID: 19710429)
1. FDA approves saxagliptin for type 2 diabetes.
Traynor K
Am J Health Syst Pharm; 2009 Sep; 66(17):1513. PubMed ID: 19710429
[No Abstract] [Full Text] [Related]
2. Saxagliptin efficacy.
Valiquette G
Diabetes Obes Metab; 2010 Aug; 12(8):734; author reply 735. PubMed ID: 20590752
[No Abstract] [Full Text] [Related]
3. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
Jialal I; Dhindsa S
Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
[No Abstract] [Full Text] [Related]
4. Saxagliptin and tuberculosis.
Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
[No Abstract] [Full Text] [Related]
5. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
Borja-Hart NL; Whalen KL
Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
[TBL] [Abstract][Full Text] [Related]
6. Saxagliptin, alogliptin, and cardiovascular outcomes.
Scirica BM; Braunwald E; Bhatt DL
N Engl J Med; 2014 Jan; 370(5):483-4. PubMed ID: 24476444
[No Abstract] [Full Text] [Related]
7. Saxagliptin + metformin. Mostly disadvantages.
Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
[No Abstract] [Full Text] [Related]
8. Saxagliptin (Onglyza) for type 2 diabetes.
Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
[No Abstract] [Full Text] [Related]
9. ACP Journal Club. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events.
Morey-Vargas OL; Montori VM
Ann Intern Med; 2014 Jan; 160(2):JC8-9. PubMed ID: 24445719
[No Abstract] [Full Text] [Related]
10. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz B
IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
[TBL] [Abstract][Full Text] [Related]
11. Saxagliptin: A Review in Type 2 Diabetes.
Dhillon S
Drugs; 2015 Oct; 75(15):1783-96. PubMed ID: 26403305
[TBL] [Abstract][Full Text] [Related]
12. Saxagliptin, alogliptin, and cardiovascular outcomes.
Standl E
N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
[No Abstract] [Full Text] [Related]
13. Baseline differences in the SAVOR trial.
Luijendijk HJ; Hulshof TA
Diabetes Obes Metab; 2015 Dec; 17(12):1202. PubMed ID: 26094750
[No Abstract] [Full Text] [Related]
14. Saxagliptin: a new drug for the treatment of type 2 diabetes.
Thareja S; Aggarwal S; Malla P; Haksar D; Bhardwaj TR; Kumar M
Mini Rev Med Chem; 2010 Jul; 10(8):759-65. PubMed ID: 20402634
[TBL] [Abstract][Full Text] [Related]
15. Metformin + saxagliptin for type 2 diabetes.
Scheen AJ
Expert Opin Pharmacother; 2012 Jan; 13(1):139-46. PubMed ID: 22149373
[TBL] [Abstract][Full Text] [Related]
16. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
Schwartz SL
Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
[TBL] [Abstract][Full Text] [Related]
17. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.
Lam S; Saad M
Cardiol Rev; 2010; 18(4):213-7. PubMed ID: 20539105
[TBL] [Abstract][Full Text] [Related]
18. Place in therapy for liraglutide and saxagliptin for type 2 diabetes and FDA liraglutide warning.
McFarland MS; Brock M; Ryals C
South Med J; 2011 Aug; 104(8):612. PubMed ID: 21886074
[No Abstract] [Full Text] [Related]
19. Saxagliptin in type 2 diabetes.
Billiones R
Drugs Today (Barc); 2010 Feb; 46(2):101-8. PubMed ID: 20393638
[TBL] [Abstract][Full Text] [Related]
20. Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.
Prescrire Int; 2011 Feb; 20(113):33-7. PubMed ID: 21488586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]